Seoul based ABL Bio is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well
Founder & CEO Sang Hoon Lee describes the science that sets ABL apart and where he sees Korea biotech headed.